Clinical Trial Update: Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and efficacy of QR-333 in symptomatic diabetic neuropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Neuropathy

Drugs mentioned

• QR-333

Snippet

Sponsor: Quigley Pharma, Inc. | Conditions: Diabetic Neuropathy | Phase 2 | Status: COMPLETED